biota has a massive pr problem !!, page-4

We know that BTA are in discussions to license LANI for the ROW market... PC was quite bullish in the papers which shocked me, he must be expecting something nice!

Agree, PR could be improved. Listing on the NASDAQ would help as more analysts take up coverage. Doubt this will happen in the short term without pressure from the larger shareholders (i.e. not us!).

I'm looking forward to the next two quarters... it's end of quarter next week (gee didn't that quarter just fly by) so am expecting another solid royalty figure. The number won't matter as much as the GSK commentary, keep an eye out for the production ramp up.

Of course the biggest news to watch out for is HRV and LANI license deals... if that doesn't grab the markets attention then I don't know what will. ASX200 inclusion still on the cards as is other "growth" announcements.

Bottom drawer for now, review time at the quarterly (end Oct?) and at license deal/s. Market cap has not cracked $1bn yet, surprising given LANI and Relenza market dynamics.